期刊
MOLECULES
卷 26, 期 14, 页码 -出版社
MDPI
DOI: 10.3390/molecules26144288
关键词
cisplatin; combinatorial therapy; doxorubicin; fucoxanthin; seaweed compounds; triple-negative breast cancer
资金
- FCT [UIDB/04423/2020, UIDP/04423/2020]
- ERDF
- Doctoral Program in Biomedical Sciences, of the ICBAS-University of Porto
Fucoxanthin has the potential to become an adjuvant for Dox chemotherapy regimens in breast cancer treatment, enhancing its cytotoxic effects and inducing cell death and genotoxic effects. In 3D cell cultures, the combination of Fx and Dox showed higher cytotoxic effects and increased apoptosis compared to isolated compounds.
Fucoxanthin (Fx) is a carotenoid derived from marine organisms that exhibits anticancer activities. However, its role as a potential drug adjuvant in breast cancer (BC) treatment is still poorly explored. Firstly, this study investigated the cytotoxic effects of Fx alone and combined with doxorubicin (Dox) and cisplatin (Cis) on a panel of 2D-cultured BC cell lines (MCF7, SKBR3 and MDA-MB-231) and one non-tumoral cell line (MCF12A). Fucoxanthin induced cytotoxicity against all the cell lines and potentiated Dox cytotoxic effects towards the SKBR3 and MDA-MB-231 cells. The combination triggering the highest cytotoxicity (Fx 10 mu M + Dox 1 mu M in MDA-MB-231) additionally showed significant induction of cell death and genotoxic effects, relative to control. In sequence, the same combination was tested on 3D cultures using a multi-endpoint approach involving bioactivity assays and microscopy techniques. Similar to 2D cultures, the combination of Fx and Dox showed higher cytotoxic effects on 3D cultures compared to the isolated compounds. Furthermore, this combination increased the number of apoptotic cells, decreased cell proliferation, and caused structural and ultrastructural damages on the 3D models. Overall, our findings suggest Fx has potential to become an adjuvant for Dox chemotherapy regimens in BC treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据